๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Growth hormone therapy in achondroplasia

โœ Scribed by Horton, William A. ;Hecht, Jacqueline T. ;Hood, O. Jean ;Marshall, Robert N. ;Moore, Wayne V. ;Hollowell, Joseph G.

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
451 KB
Volume
42
Category
Article
ISSN
0148-7299

No coin nor oath required. For personal study only.

โœฆ Synopsis

A pilot study was carried out to examine the safety and efficacy of recombinant human growth hormone for growth-promoting therapy of achondroplasia. The data suggest that the agent in doses used to treat non-GH-deficient forms of short stature (0.3 mg/kg/wk) modestly increases overall height velocity in some children with achondroplasia. The effect was seen mainly in children with the lowest growth velocities prior to treatment. No untoward effects were noted. Several questions were raised that require further study.

๐Ÿ“œ SIMILAR VOLUMES

Growth and growth hormone therapy in chi
Growth and growth hormone therapy in children with achondroplasia: A two-year experience
โœ Stamoyannou, L.; Karachaliou, F.; Neou, P.; Papataxiarchou, K.; Pistevos, G.; Ba ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 35 KB ๐Ÿ‘ 3 views

The efficacy and safety of recombinant human growth hormone (hGH) administration was studied in children with achondroplasia. Fifteen children with achondroplasia, seven boys (4.8-12.2 years of age) and 12 girls (5.7-2.2 years of age), were treated daily with hGH at a dosage of 1 IU/kg/week. Auxolog

Human growth hormone treatment in prepub
Human growth hormone treatment in prepubertal children with achondroplasia
โœ Weber, Giovanna; Prinster, Chiara; Meneghel, Marta; Russo, Fiorella; Mora, Stefa ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 22 KB ๐Ÿ‘ 3 views

We studied the effects of recombinant human growth hormone (GH) treatment in 6 prepubertal children with achondroplasia. The patients' age ranged from 2'!'12 to 85/12 years and the GH dose was of 0.1 IU/kg/ day subcutaneously. Auxological assessments and bone age determinations were performed 6 mont

Growth hormone therapy and leukaemia
Growth hormone therapy and leukaemia
โœ N. Stahnke; H. J. Zeisel ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› Springer ๐ŸŒ English โš– 611 KB

Following an initial report from Japan in 1987, 15 growth hormone (GH)-deficient patients developed leukaemia during or following GH treatment. Nearly all available pituitary and biosynthetic growth hormones have been used. In 14 of these 15 patients GH treatment was initiated in 1975 or later with